EXHIBIT 2

November 13, 2020, Email Exchange

FILED UNDER SEAL

EXHIBIT 2

On Nov 13, 2020, at 10:45 AM, Stephen Hurst <shurst@mindmed.co> wrote:

Dear Carey,

First let me thank you for even considering letting MindMed (MMED) purchase a portion of the LSD produced in the current manufacturing campaign for BOL-148 at Onyx. I know that it's taken CH TAC about two years to get to this point ad that it is a sacrifice to take a lower yield of BOL in order to assist MINIED at this time.

Please confirm that the following four points are the material terms of the letter agreement that will cover this transaction between MindMed and CH TAC in order for MMED to receive approximately 50 grams of GMP LSD from your current production run at Onyx:

- MMED will make a cash payment of \$300,000 to CH TAC upon execution of the agreement;
- MMED will supply 50 grams of GMP LSD to CH TAC when it manufactures the material next year;
- MMED agrees not to manufacture BOL-148 or otherwise compete with CH TAC on BOL-148 without prior written consent from CH TAC; and,
- MMED agrees not to assert any LSD molecule intellectual property against CH TAC such that CH TAC maintains the same freedom to operate with respect to the LSD molecule it has today going forward. Such intellectual property could be in the form of patent claims covering the LSD composition of matter, polymorphs or product-by-process.

Once you have confirmed the above I will forward this email to the MMED Executive Committee for their approval of the transaction and, if approved, will draft a letter agreement as soon as possible for your review and signature.

Thank you again,

Steve

Stephen L. Hurst
Executive Chair & Co-CEO
Mind Medicine (MindMed), Inc.
One World Trade Center, Suite 8500
New York, NY 10007
Main: 1.212.220.6633 (MMED)
Mobile: 1.650.208.2454
Sheiter-In-Place No.: 1.707.937.3792
shurst@mindmed.co

From: Carey Turnbull < careyt@me.com >
Date: Friday, November 13, 2020 at 8:04 AM
To: Stephen Hurst < shurst@mindmed.co >

Subject: Re: GMP LSD

I agree to these terms, and look forward to executing the written agreement. I'm pleased to be in a position to help MindMed achieve its important research goals as quickly as possible for the benefit of those whose its medicines may help.

Thanks as always Steve for the efforts you make to alleviate suffering.

Carey

From: Staphen Hurst <shurst@mindmed.co> Sent: Friday, November 13, 2020 11:13 AM

To: miri.halperin.wernli@gmail.com <miri.halperin.wernli@gmail.com>; Carol Nast <cnast@mindmed.co>; JR Rahn

<jr@minamed.co>

Subject: URGENT: FW: GMP LSD

EC Members,

Sorry but this one can't wait until Tuesday. Time is of the essence as the BOL production run is starting.

Please review and hopefully approve the following. LMK if we need to get on a Zoom and discuss.

1

I'm at the ranch if you need to call me - 1.707.937.3792.

Cheers,

S

Stephen L. Hurst
Executive Chair & Co-CEO
Mind Medicine (MindMed), Inc.
One World Trade Center, Suite 8500
New York, NY 10007
Main: 1.212.220.6633 (MMED)
Mobile: 1.650.208.2454

Sheiter-In-Place No.: 1.707.937.3792

shurst@mindmed.co

From: JR Rahn < jr@mindmed.co>

Date: Friday, November 13, 2020 at 9:24 AM

To: Stephen Hurst <shurst@mindmed.co>, "miri.halperin.wernli@gmail.com"

<miri.halperin.wernli@gmail.com>, Carol Nast <cnast@mindmed.co>

Subject: Re: URGENT: FW: GMP LSD

-BOL-148 Non-Compete should be limited to Cluster Headaches which is where he has his patent and focus. If he wants freedom to operate on LSD, we should get the same ex-Cluster headaches

-Freedom to operate should be specific to manufacturing process (we cannot give the house away on our programs we are investing millions of public investor money into Anxiety and Adult ADHD). Does he propose a license of our IP in LSD?

These are quite material decisions and very one sided demands.

From: Stephen Hurst <shurst@mindmed.co> Sent: Friday, November 13, 2020 12:49 PM

To: JR Rahn <jr@mindmed.co>; miri.halperin.wernli@gmail.com <miri.halperin.wernli@gmail.com>; Carol Nast

<cnast@mindmed.co>

Subject: Re: URGENT: FW: GMP LSD

Molecule not indication or the deal is off. Already covered that ground and he is already expanding beyond CH.